AIM (AIM ImmunoTech) Cyclically Adjusted Revenue per Share: $16.69 (As of Mar. 2026)


AIM AIM ImmunoTech Inc AIM
33 GF Score
Price $0.28
GF Value $2.57
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AIM ImmunoTech Cyclically Adjusted Revenue per Share?

AIM ImmunoTech AIM -3.07% 33 Cyclically Adjusted Revenue per Share is $16.69 as of Mar. 2026. GuruFocus rates AIM with a GF Score™ of 33/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AIM ImmunoTech's adjusted revenue per share for the three months ended in Mar. 2026 was $0.005. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $16.69 for the trailing ten years ended in Mar. 2026.

During the past 12 months, AIM ImmunoTech's average Cyclically Adjusted Revenue Growth Rate was -17.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -19.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -17.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -21.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AIM ImmunoTech was 7.30% per year. The lowest was -44.10% per year. And the median was -13.80% per year.

As of today (2026-07-09), AIM ImmunoTech's current stock price is $0.2811. AIM ImmunoTech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $16.69. AIM ImmunoTech's Cyclically Adjusted PS Ratio of today is 0.02.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AIM ImmunoTech was 40.19. The lowest was 0.01. And the median was 2.65.


AIM ImmunoTech  (AMEX:AIM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AIM ImmunoTech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.2811/16.69
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AIM ImmunoTech was 40.19. The lowest was 0.01. And the median was 2.65.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AIM ImmunoTech Cyclically Adjusted Revenue per Share Related Terms


AIM ImmunoTech Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for AIM ImmunoTech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech Cyclically Adjusted Revenue per Share Chart

AIM ImmunoTech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.31 33.53 27.96 21.20 17.47

AIM ImmunoTech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.23 18.78 18.27 17.47 16.69

AIM vs RVPH, BOLT, ERNA: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, AIM ImmunoTech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Cyclically Adjusted PS Ratio falls into.


AIM
33GF Score
AIM ImmunoTech Inc AIM
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AIM ImmunoTech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AIM ImmunoTech's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.005/330.2130*330.2130
=0.005

Current CPI (Mar. 2026) = 330.2130.

AIM ImmunoTech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 3.000 241.018 4.110
201609 4.400 241.428 6.018
201612 3.200 241.432 4.377
201703 14.000 243.801 18.962
201706 35.500 244.955 47.856
201709 12.857 246.819 17.201
201712 7.143 246.524 9.568
201803 7.000 249.554 9.262
201806 3.300 251.989 4.324
201809 3.455 252.439 4.519
201812 21.818 251.233 28.677
201903 0.000 254.202 0.000
201906 1.526 256.143 1.967
201909 2.346 256.759 3.017
201912 0.481 256.974 0.618
202003 0.257 258.115 0.329
202006 0.133 257.797 0.170
202009 0.093 260.280 0.118
202012 0.103 260.474 0.131
202103 0.061 264.877 0.076
202106 0.048 271.696 0.058
202109 0.069 274.310 0.083
202112 0.104 278.802 0.123
202203 0.069 287.504 0.079
202206 0.062 296.311 0.069
202209 0.044 296.808 0.049
202212 0.116 296.797 0.129
202303 0.101 301.836 0.110
202306 0.087 305.109 0.094
202309 0.094 307.789 0.101
202312 0.133 306.746 0.143
202403 0.081 312.332 0.086
202406 0.095 314.175 0.100
202409 0.061 315.301 0.064
202412 0.070 315.605 0.073
202503 0.023 319.799 0.024
202506 0.033 322.561 0.034
202509 0.012 324.800 0.012
202512 0.007 324.054 0.007
202603 0.005 330.213 0.005

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $16.69 mean?
AIM ImmunoTech (AIM) has a Cyclically Adjusted Revenue per Share of $16.69 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AIM ImmunoTech and its competitors.
Is AIM ImmunoTech's Cyclically Adjusted Revenue per Share too high?
AIM ImmunoTech's current Cyclically Adjusted Revenue per Share is $16.69. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's Cyclically Adjusted Revenue per Share compare to RVPH and BOLT?
AIM ImmunoTech's Cyclically Adjusted Revenue per Share of $16.69 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current Cyclically Adjusted Revenue per Share is $16.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $0.28 — trading 89.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $16.69. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current Cyclically Adjusted Revenue per Share is $16.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AIM ImmunoTech (AIM) Overvalued in 2026?

Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued. The current stock price of $0.28 is trading 89.1% below its estimated GF Value™ of $2.57. GuruFocus considers AIM ImmunoTech to be Possible Value Trap.

Key valuation signals for AIM:

  • Cyclically Adjusted Revenue per Share: $16.69
  • GF Value™: $2.57 vs. price of $0.28 (89.1% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AIM ImmunoTech Business Description

Other Exchanges 0A4Y:UK
Address 2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score

Get the complete analysis for AIM

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price
$2.57
GF Value